The first published data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study supports the hypothesis that higher levels of the amyloid protein in the brain represent an early stage of Alzheimer’s disease. Results of an analysis of participant screening data for the study, published April 6 in JAMA Neurology, also show that amyloid burden in clinically normal older adults is associated with a family history of disease, lower cognitive test scores, and reports of declines in daily cognitive function. Major funding was provided by the National Institute on Aging (NIA), part of the National Institutes of Health; all data is now freely available to the broader research community.
The continued availability of medicines, in particular those used for patients with COVID-19, is of critical concern for EMA and its partners in the European medicines regulatory network in light of the medical emergency presented by the pandemic.
In a dedicated COVID-19 workshop, organised by the European Medicines Agency (EMA) under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), international regulators discussed how data generated during clinical practice could complement evidence from clinical trials with potential therapeutics or vaccines against COVID-19. Participants from more than 25 countries, representing 28 medicines regulatory authorities globally and experts from the World Health Organization and the European Commission acknowledged the importance of observational studies of real world data for increasing the effectiveness and efficiency of regulatory processes and decision-making in the development, authorisation and monitoring of medicines and vaccines to prevent and treat COVID-19 and to address knowledge gaps that cannot be addressed by clinical trials.
HLL has introduced rapid diagnostic kit under the brand name Make Sure for the quick detection of Corona virus. The test result will be available within 15 to 20 minutes. The test kit is being manufactured at HLL Manesar Factory, Gurgaon.
The Council of Scientific and Industrial Research (CSIR) has adopted a five-tier strategy to fight Covid-19, which is also getting wide support from the industry to implement it. This information was provided by Dr. Shekhar C. Mande, Director General of CSIR. He was addressing an online zoom meeting with directors of 38 laboratories of CSIR to discuss the strategy related to Covid-19.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
